For nearly two decades, Kid Risk, Inc. has developed and applied integrated analytical models to support individual and public policy decisions related to vaccines and vaccine-preventable diseases, particularly for polioviruses, as well as measles & rubella. This work continues to lead to multiple publications each year related to modeling and managing the transmission of vaccine-preventable diseases, and it represents a primary focus area for Kid Risk, Inc.

Contribution of vaccination to improved survival and health: Modelling 50 years of the Expanded Programme on Immunization

Shattock AJ, Johnson HC, Sim SY, Carter A, Lambach P, Hutubessy RCW, Thompson KM, Badizadegan K, Lambert B, Ferrari MJ, Jit M, Fu H, Silal SP, Hounsell RA, White RG, Mosser JF, Gaythorpe KAM, Trotter CL, Lindstrand A, O'Brien KL, Bar-Zeev N

Lancet, 2024; 403(10441):2307-2316, doi:10.1016/S0140-6736(24)00850-X.

Excess vaccine-preventable disease mortality due to COVID-19

Thompson KM

Lancet Glob Health, 2024; 12(4):e531-e532. doi:10.1016/S2214-109X(24)00046-9.

The impact of disruptions caused by the COVID-19 pandemic on global polio eradication

Kalkowska DA, Voorman A, Pallansch MA, Wassilak SGF, Cochi SL, Badizadegan K, Thompson KM

Vaccine, 2023; 41 Suppl 1:A12-A18. doi:10.1016/j.vaccine.2021.04.026.

Health economic analysis of antiviral drugs in the global polio eradication endgame

Badizadegan K, Kalkowska DA, Thompson KM

Med Decis Making, 2023:272989x231191127. doi:10.1177/0272989x231191127.

Polio health economics: Assessing the benefits and costs of polio, non-polio, and integrated activities of the Global Polio Eradication Initiative

Thompson K, Kalkowska D, Badizadegan K

Gates Open Research, 2022; 6(5). doi:10.12688/gatesopenres.13524.1. [version 1; peer review: 2 approved]

Health economic analyses of secondary vaccine effects: A systematic review and policy insights

Thompson KM, Badizadegan K

Expert Rev Vaccines, 2022:1-16. doi:10.1080/14760584.2022.2017287.

NIAID workshop on secondary vaccine effects

Secondary Vaccine Effects Workshop Planning Committee

Nat Immunol, 2021; 22(11):1363-1366. doi:10.1038/s41590-021-01054-5.

A health economic analysis for oral poliovirus vaccine to prevent COVID-19 in the United States

Thompson KM, Kalkowska DA, Badizadegan K

Risk Anal, 2021; 41(2):376-386. doi:10.1111/risa.13614.

Hypothetical emergence of poliovirus in 2020: Part 1. Consequences of policy decisions to respond using nonpharmaceutical interventions

Thompson KM, Kalkowska DA, Badizadegan K

Expert Rev Vaccines, 2021. doi:10.1080/14760584.2021.1891888.

Hypothetical emergence of poliovirus in 2020: Part 2. Exploration of the potential role of vaccines in control and eradication

Thompson KM, Kalkowska DA, Badizadegan K

Expert Rev Vaccines, 2021. doi:10.1080/14760584.2021.1891889.

An updated economic analysis of the global polio eradication initiative

Thompson KM, Kalkowska DA

Risk Anal, 2021; 41(2):393-406. doi:10.1111/risa.13665.

Health and economic outcomes associated with polio vaccine policy options: 2019–2029

Kalkowska DA, Thompson KM

Risk Anal, 2021; 41(2):364-375. doi:https://doi.org/10.1111/risa.13664.

Valuing health outcomes: Developing better defaults based on health opportunity costs

Ochalek J, Claxton K, Lomas J, Thompson KM

Expert Rev Pharmacoecon Outcomes Res, 2020:1-8. doi:10.1080/14737167.2020.1812387.

An opportunity to incentivize innovation to increase vaccine safety in the United States by improving vaccine delivery using vaccine patches

Thompson KM, Orenstein WA, Hinman AR

Vaccine, 2020. doi:10.1016/j.vaccine.2020.04.044.

The potential role of using vaccine patches to induce immunity: Platform and pathways to innovation and commercialization

Badizadegan K, Goodson JL, Rota PA, Thompson KM

Expert Rev Vaccines, 2020; 19(2):175-194. doi:10.1080/14760584.2020.1732215.

Performance of the United States Vaccine Injury Compensation Program (VICP): 1988–2019

Thompson KM, Orenstein WA, Hinman AR.

Vaccine, 2020. doi: 10.1016/j.vaccine.2020.01.042. Epub 2020 Jan 22.

The National Vaccine Advisory Committee at 30: Impact and opportunity

Thompson KM, Gellin BG, Hinman AR, Orenstein WA

Vaccine, 2018; 36(11):1330-1344. doi:10.1016/j.vaccine.2018.01.068.

Systematic review of the incremental costs of interventions that increase immunization coverage

Ozawa S, Yemeke TT, Thompson KM

Vaccine, 2018; 36(25):3641-3649. doi:10.1016/j.vaccine.2018.05.030.

Strengthening the effectiveness of national, state, and local efforts to improve HPV vaccination coverage in the United States: recommendations From the National Vaccine Advisory Committee

National Vaccine Advisory Committee

Public Health Rep, 2018; 133(5):543-550. doi:10.1177/0033354918793629.

Using integrated modeling to support the global eradication of vaccine-preventable diseases

Duintjer Tebbens RJ, Thompson KM

System Dynamics Review, 2018; 34(1-2):78-120. doi:10.1002/sdr.1589.

Key steps forward for maternal immunization: Policy making in action

Beigi RH, Omer SB, Thompson KM

Vaccine, 2018; 36(12):1521-1523. doi:10.1016/j.vaccine.2018.02.041.

Evaluation of the 2010 National Vaccine Plan mid-course review: recommendations From the National Vaccine Advisory Committee: Approved by the National Vaccine Advisory Committee on February 7, 2017

National Vaccine Advisory Committee

Public Health Rep, 2017; 132(4):411-430. doi:10.1177/0033354917714233.

Overcoming barriers and identifying opportunities for developing maternal immunizations: recommendations from the National Vaccine Advisory Committee

National Vaccine Advisory Committee

Public Health Rep, 2017; 132(3):271-284. doi:10.1177/0033354917698118.

Characterization of heterogeneity in childhood immunization coverage in central Florida using immunization registry data

Thompson KM, Logan GE, Florida SRT

Risk Anal, 2016; 36(7):1418-26. doi:10.1111/risa.12424.

Framework for optimal global vaccine stockpile design for vaccine-preventable diseases: application to measles and cholera vaccines as contrasting examples

Thompson KM, Duintjer Tebbens RJ

Risk Anal, 2016; 36(7):1487-509. doi:10.1111/risa.12265.

A call for greater consideration for the role of vaccines in national strategies to combat antibiotic-resistant bacteria: Recommendations from the National Vaccine Advisory Committee: Approved by the National Vaccine Advisory Committee on June 10, 2015

National Vaccine Advisory Committee

Public Health Rep, 2016; 131(1):11-6. doi:10.1177/003335491613100105.

Overcoming barriers to low HPV vaccine uptake in the United States: Recommendations from the National Vaccine Advisory Committee: Approved by the National Vaccine Advisory Committee on June 9, 2015

National Vaccine Advisory Committee

Public Health Rep, 2016; 131(1):17-25. doi:10.1177/003335491613100106.

Assessing the state of vaccine confidence in the United States: recommendations from the National Vaccine Advisory Committee: Approved by the National Vaccine Advisory Committee on June 9, 2015

National Vaccine Advisory Committee

Public Health Rep, 2015; 130(6):573-95. doi:10.1177/003335491513000606.

Managing cholera as a preventable global threat

Thompson KM, Duintjer Tebbens RJ, Chaignat CL, Hill A, Costa AJ, Badizadegan K, Namgyal P, Hutubessy RC

J Vaccines Vaccin, 2013; 4(183):1000183. doi:10.4172/2157-7560.1000183.

Development of investment cases for globally-coordinated management of infectious diseases

Thompson KM, Duintjer Tebbens RJ

J Vaccines Vaccin, 2012; 3(8):164. doi:10.4172/2157-7560.1000164.

Global ICU: Valuing prevention as the new paradigm in global health

Thompson KM

ICU Management, 2012; 12(4):9-11.

Group report: Developing an eradication investment case

Thompson KM, Rabinovich R, Conteh L, Emerson CI, Hall BF, Singer PA, Vijayaraghavan M, Walker DG

In Disease Eradication in the 21st Century: Implications for Global Health. Cochi SL and Dowdle WR (eds). Cambridge, MA: MIT Press: 2011; 133-148.

Economic evaluation of the benefits and costs of disease elimination and eradication initiative

Thompson KM, Duintjer Tebbens RJ

In Disease Eradication in the 21st Century: Implications for Global Health. Cochi SL and Dowdle WR (eds). Cambridge, MA: MIT Press: 2011; 115-130.

Priority shifting and the dynamics of managing eradicable infectious diseases

Duintjer Tebbens RJ, Thompson KM

Manag Sci, 2009; 55(4):650-63. doi:10.1287/mnsc.1080.0965.

Uncertainty and sensitivity analyses of a dynamic economic evaluation model for vaccination programs

Duintjer Tebbens RJ, Thompson KM, Hunink MG, Mazzuchi TA, Lewandowski D, Kurowicka D, Cooke RM

Med Decis Making, 2008; 28(2):182-200. doi:10.1177/0272989X07311752.

The Lyme vaccine: a cautionary tale

Nigrovic LE, Thompson KM

Epidemiol Infect, 2007; 135(1):1-8. doi:10.1017/s0950268806007096.

Emerging issues in vaccine economics: Perspectives from the USA

Lieu TA, Thompson KM, Prosser LA, O'Brien MA, Yusuf HR, Shefer AM, Weinstein MC, Rickert DL

Expert Rev Vaccines, 2002; 1(4):433-42. doi:10.1586/14760584.1.4.433.

©2025 Kid Risk, Inc. All rights reserved.